



Report on Utilization of IPO Proceeds
For the Month of February 2019

Name of the Company: : The ACME Laboratories Ltd.
Amount (BDT) of capital raised through IPO: : BDT 4,096,000,000 (Received amount BDT 4,095,015,601.38 net of foreign currency conversion loss)
Date of Close of Subscription: : 21 April 2016
Proceeds Receiving Date: : 11 April 2016 to 21 April 2016
Last Date of Full Utilization of IPO Fund as per 40th AGM/42nd AGM : As stated in time line columns

S/L	Purpose mentioned in the 40th AGM/42nd AGM	Time Line		Cost Breakdown	Amount as per 40th AGM	Amount as per 42nd AGM	Opening	During the Month	Status of Utilization		Total un utilized amount	Un utilized %	Remarks	
		As per 40th AGM	As per 42nd AGM						Total Utilized Amount	Utilized %				
1	Steroid and Hormone Project	Within 2 years of receiving IPO fund, i.e. 2018	Within June 2019	Civil Construction Machinery & Equipment Utility Warehouse Vehicle Contingency fee Contingencies Sub Total	335,800,000 598,600,000 339,600,000 39,500,000 5,000,000 26,300,000 13,200,000 1,358,000,000	334,934,878 933,900,000 353,700,000 21,986,000 5,000,000 1,200,000 9,870,308 1,660,591,186	334,934,878 933,900,000 353,700,000 21,986,000 5,000,000 1,200,000 9,870,308 1,660,591,186	-	334,934,878 933,900,000 353,700,000 21,986,000 5,000,000 1,200,000 9,870,308 1,660,591,186	100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%	-	0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%		
2	Penicillin Project	Within the month of March 2018	Within June 2019	Civil Construction Machinery & Equipment Utility Warehouse Vehicle Contingency fee Contingencies Sub Total	116,000,000 132,299,520 117,154,000 20,582,700 3,000,000 5,963,780 5,000,000 400,000,000	142,922,303 79,768,602 146,345,797 21,641,545 2,901,503 1,420,250 5,000,000 355,637,904	142,922,303 79,768,602 146,345,797 21,641,545 2,901,503 1,420,250 5,000,000 355,637,904	-	142,922,303 79,768,602 146,345,797 21,641,545 2,901,503 1,420,250 5,000,000 355,637,904	100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%	-	0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	Rearrangement of Utilization Plan has been approved in 42nd AGM as on 6 December 2018 and IPO Utilization Proceeds certified by M/s Pinaki and Company, Chartered Accountants	
3	Active Pharmaceuticals Ingredients (API)	Within 2-3 years after getting permission from the Ministry of Industries	Within June 2022	Machinery & Equipment Utility Warehouse Vehicle Contingency fee Contingencies Initial Working Capital Sub Total	493,000,000 409,400,000 38,500,000 3,000,000 23,635,200 12,917,600 26,915,492 1,355,228,292	250,495,241 - - - - - - 606,132,545	-	-	-	-	-	-	-	
4	Repayment of Bank Borrowing at 40th AGM	N/A	N/A		1,360,000,000	1,360,000,000	1,360,000,000	-	-	1,360,000,000	100.00%	-	0.00%	
5	IPO Expenses	N/A	N/A		68,291,870	68,291,870	68,291,870	-	-	68,291,870	100.00%	-	0.00%	
Total					4,541,520,162	4,095,015,601	3,640,170,080	-	-	3,640,170,080	88.89%	454,845,521	11.11%	

Percentage (Interest on FDR to be matured on 27 March 2019 & 06 April 2015)
Interest on IPO Proceeds in BDT (from FDR & SND)
Un-Utilized IPO Proceeds with interest income in BDT

On Behalf of Board

Fouzia Haque, CMA
Independent Director & Chairman of the Audit Committee

Mizanur Rahman Sinha
Managing Director

Nagina Afral Sinha
Chairman

12/03/19
Pinaki & Company
Chartered Accountants